Phase 2 N=82 Acupuncture for Chronic Lymphedema
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=202 S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer · Gastric Cancer
Primary: Progression-free Survival (PFS) in High-ERCC1 Patients — 4.7; 5.3 months — p=0.83
Phase 2 N=62 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Pleuropulmonary Blastoma · Recurrent Malignant Peripheral Nerve Sheath Tumor · Recurrent Neuroblastoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants
Phase 2 N=351 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore
Dengue Fever
Primary: Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 15 — 156.2; 110.2; 183.0; 117.6 Titer
Phase 2 N=43 Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Prostate Cancer · Bladder Cancer · Kidney Cancer
Primary: Percentage Change (From Baseline to 24 Hours) Between Metastatic and Benign Nodes — -33.6; -46.9 Percentage Change
Phase 2 N=28 Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Lymphoma
Primary: Progression-free Survival at 1 Year — 38 percentage of participants
Phase 2 N=20 A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
Bladder Cancer · Pancreas Cancer · Cholangiocellular Carcinoma
Primary: Best Overall Response (BOR) Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1). — 0; 0; 38.5; 14.3 Percentage of Treated…
Phase 2 N=13 Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
Chronic Hepatitis B
Primary: Change in Interferon-stimulated-gene (ISG) Expression — -2.716; 1.670; -2.20; -1.597 log 2 fold change
Phase 2 N=14 Phase 2 Study With SNF472 in Calciphylaxis Patients
Calciphylaxis · Calcific Uremic Arteriolopathy
Primary: Wound Healing — -8.1 units on a scale — p=<0.001
Phase 2 N=65 Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Amyotrophic Lateral Sclerosis
Primary: Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) — 1.180; 0.965; 0.784; 1.347 Unitless
Phase 2 N=53 Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
Heart Transplantation · Liver Transplantation · Kidney Transplantation
Primary: Time to Achieve Therapeutic Tacrolimus Drug Concentrations — 4.7; 3.4 Days
Phase 2 N=133 A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
Lung Cancer, Non-Small Cell
Primary: Time to Occurrence of Any Recurrence of Disease — 0.217; 0.067 person-year rate — p=0.1422
Phase 2 N=32 Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.
Lung Transplant Infection · Lower Respiratory Tract Infection
Primary: Lung Clearance Index 2% (LCI2%) — 10.68; 11.65; 10.09; 11.19 Index (change)
Phase 2 N=350 A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis
Knee Osteoarthritis · Medial Compartment Knee Osteoarthritis
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16 — -8.9; -9.2; -11.8; -10.1 score…
Phase 2 N=3 Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Primary: Overall Survival Rate — 0 percentage of participants alive